Physician profile
Rhea Hsu
NPI 1952394744
$11,392.12
in general payments reported to CMS, 2019-2025
57 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,984 · 2020: $1,655 · 2021: $2,580 · 2022: $2,905 · 2023: $2,123 · 2024: $19.98 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,267 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,266.98 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,726.45 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $1,368.93 | 2019-2023 | |
| Abbvie INC. | $897.69 | 2021-2023 | |
| Astellas Pharma US INC | $673.55 | 2019-2023 | Veozah, Myrbetriq |
| Lilly USA, LLC | $662.14 | 2019-2023 | Mounjaro, Jardiance, Emgality |
| Pfizer INC. | $636.03 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $537.14 | 2019-2023 | Farxiga |
| Amgen INC. | $502.87 | 2019-2023 | Repatha, Otezla, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $386.71 | 2019-2023 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $372.70 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $264.36 | 2019-2022 | |
| Nevro Corp. | $259.16 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $245.32 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $240.06 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $208.89 | 2022 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rhea Hsu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.